TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00802334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: generic lopinavir/ritonavir
Description: 1. Screening visit~   • Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~2. Baseline visit~   • (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~3. Week 4~   * Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment
Study: NCT00019682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study: NCT03816202

Intervention type: DEVICE
Intervention: Sundt carotid shunt
Description: The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
Study: NCT02241200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA3880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aranesp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aranesp
Study: NCT04143997

Intervention type: DIAGNOSTIC_TEST
Intervention: A clinical Transthoracic echocardiogram
Description: A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
Study: NCT03576469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor [recombinant] (C1-INH-R)
Description: C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
Study: NCT03307902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imiquimod + ID HBVv
Description: Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous + ID HBVv
Description: Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod + IM HBVv
Description: Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
Study: NCT01506063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg
Study: NCT03455114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AssiAnchor
Description: The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule.
Study: NCT04534088

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss plus Non-Weight-Related VR app
Description: Standard Behavioral Weight Loss Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Loss plus Weight-Related VR app
Description: Standard Behavioral Weight Loss plus Weight-Related VR app
Study: NCT00710086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
Study: NCT00265863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
Study: NCT03463824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 1
Description: Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group 2
Description: Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
Study: NCT03904667

Intervention type: OTHER
Intervention: Watson on oncology surgery decision evaluation
Description: Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.

Intervention type: OTHER
Intervention: Watson on oncology surgery decision evaluation
Description: Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
Study: NCT01878500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative stereotactic imaging with VectorVision
Description: Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
Study: NCT02007187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danhong injection
Description: A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT01844869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Study: NCT00019682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 Antigen
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00649155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Extended-Release Tablets 500 mg
Description: 500mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro® XR Tablets (500 mg
Description: 500mg, single dose fasting
Study: NCT03858660

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00530452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: Dual-acting COX-2 inhibitor \& carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
Study: NCT00801827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 (fallypride)
Description: Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
Study: NCT03384758

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compression Therapy
Description: Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
Study: NCT00530452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silicified microcrystalline cellulose + talc
Description: Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
Study: NCT04405024

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hepatitis C testing
Description: Hepatitis C Screening
Study: NCT02137252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study: NCT04468425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib Citrate
Description: Period 1: Xelijanz® 5 mg tablet (tofacitinib citrate) for single oral dosing. Period 2: Tofacitinib Citrate Topical Gel 3.2% for repeat topical dosing BID for 14 days.
Study: NCT02001311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Study: NCT02308969

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 100ug per os, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD
Study: NCT03953976

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
Study: NCT01742546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound combine TENS
Description: Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic ultrasound combine TENS
Description: Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius).
Study: NCT03901794

Intervention type: DEVICE
Intervention: Non-invasive hemodynamic monitor
Description: MAP, HR, CO, SVI, from Non-invasive hemodynamic monitor
Study: NCT03588403

Intervention type: RADIATION
Intervention: TOMO
Description: Tomotherapy

Intervention type: RADIATION
Intervention: IMRT
Description: Intensity modulated radiotherapy
Study: NCT02347813

Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone
Description: 15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone
Description: 15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
Study: NCT03526328

Intervention type: OTHER
Intervention: EMR and RFA effect on stem cell marker expression in BE/EAC
Description: Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
Study: NCT02125383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
Study: NCT01984229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
Study: NCT00176501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
Study: NCT04108312

Intervention type: DIAGNOSTIC_TEST
Intervention: Anatomical MRI Scan
Description: T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)

Intervention type: DIAGNOSTIC_TEST
Intervention: Anatomical MRI Scan
Description: T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
Study: NCT04631666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
Study: NCT02823145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Study: NCT02331992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence program
Description: Participants will receive supportive messages while enrolled in the program.
Study: NCT01538745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
Study: NCT00725894

Intervention type: DEVICE
Intervention: Pediatric Locking Nail
Description: The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
Study: NCT02332031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
Study: NCT01813500

Intervention type: OTHER
Intervention: Blood and stool sample
Description: Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.

Intervention type: OTHER
Intervention: Blood and stool sample
Description: Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
Study: NCT01538017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiapex
Description: Collagenase Clostridium Histolyticum
Study: NCT02586857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).
Study: NCT01538017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous needle fasciotomy
Description: Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
Study: NCT01924325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: orally active direct factor Xa inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: orally active direct factor Xa inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: a non-steroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT04299737

Intervention type: OTHER
Intervention: Treatment Bundle (as defined below)
Description: Patient decolonization within one hour of incision, improved environmental cleaning (frequency and quality, including but not limited to targeted use of no touch disinfection with UV-C treatment), provider hand hygiene leveraging proximity, improved catheter disinfection, and surveillance optimization.
Study: NCT00727896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-coded messages
Description: Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Treatment
Description: Life style modification and drug therapy